{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Igarashi KJ"],"funding":["Cancer Research UK","NIDDK NIH HHS","NHLBI NIH HHS","Medical Research Council","NCI NIH HHS","Wellcome Trust"],"pagination":["3366-3377"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10345863"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(14)"],"pubmed_abstract":["Hematopoietic stem cells (HSCs) are a rare type of hematopoietic cell that can entirely reconstitute the blood and immune system after transplantation. Allogeneic HSC transplantation (HSCT) is used clinically as a curative therapy for a range of hematolymphoid diseases; however, it remains a high-risk therapy because of its potential side effects, including poor graft function and graft-versus-host disease (GVHD). Ex vivo HSC expansion has been suggested as an approach to improve hematopoietic reconstitution in low-cell dose grafts. Here, we demonstrate that the selectivity of polyvinyl alcohol (PVA)-based mouse HSC cultures can be improved using physioxic culture conditions. Single-cell transcriptomic analysis helped confirm the inhibition of lineage-committed progenitor cells in physioxi"],"journal":["Blood advances"],"pubmed_title":["Physioxia improves the selectivity of hematopoietic stem cell expansion cultures."],"pmcid":["PMC10345863"],"funding_grant_id":["T32 CA196585","R01 DK116944","R01 HL147124","K99 HL150218","MC_UU_00016/18"],"pubmed_authors":["Igarashi KJ","Gottgens B","Czechowicz A","Bridge KS","Ho PY","Chan YY","Kealy D","Hickey JW","Wilkinson AC","Khoo HM","Nakauchi H","Kucinski I","Nolan GP","Tan TK","Bhadury J","Niizuma K","Hsu I"],"additional_accession":[]},"is_claimable":false,"name":"Physioxia improves the selectivity of hematopoietic stem cell expansion cultures.","description":"Hematopoietic stem cells (HSCs) are a rare type of hematopoietic cell that can entirely reconstitute the blood and immune system after transplantation. Allogeneic HSC transplantation (HSCT) is used clinically as a curative therapy for a range of hematolymphoid diseases; however, it remains a high-risk therapy because of its potential side effects, including poor graft function and graft-versus-host disease (GVHD). Ex vivo HSC expansion has been suggested as an approach to improve hematopoietic reconstitution in low-cell dose grafts. Here, we demonstrate that the selectivity of polyvinyl alcohol (PVA)-based mouse HSC cultures can be improved using physioxic culture conditions. Single-cell transcriptomic analysis helped confirm the inhibition of lineage-committed progenitor cells in physioxi","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-06-02T12:03:29.193Z","creation":"2026-04-18T03:11:18.446Z"},"accession":"S-EPMC10345863","cross_references":{"pubmed":["36809781"],"doi":["10.1182/bloodadvances.2023009668"]}}